Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric glioma with a BRAF V600E | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending | |||
Tagrisso | Osimertinib | Non-Small Cell Lung Cancer (NSCLC) (first line) | Reimburse with clinical criteria and/or conditions | Complete | ||
Tagrisso | osimertinib | Non-small cell lung cancer | Active | |||
Tagrisso | Osimertinib | Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Tagrisso | osimertinib | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Takhzyro | lanadelumab | Hereditary angioedema, prevention | Reimburse with clinical criteria and/or conditions | Complete | ||
Taltz | ixekizumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | ||
Taltz | Ixekizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Taltz | ixekizumab | Ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete |